NCT03460067View on ClinicalTrials.gov

Omission of Radiation in Patients With Her-2 Positive Breast Cancer

NAActive, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 23, 2018

Primary Completion Date

July 16, 2027

Study Completion Date

July 16, 2027

Conditions
HER2-positive Breast Cancer
Interventions
RADIATION

Omission of Radiation

No Radiation will be given. 1 year of trastuzumab +/- pertuzumab treatment will be given with 5 years of follow up occurring every 3 months to check for recurrence

Trial Locations (1)

66190

University of Kansas Medical Center/ Cancer Center, Kansas City

All Listed Sponsors
lead

University of Kansas Medical Center

OTHER

NCT03460067 - Omission of Radiation in Patients With Her-2 Positive Breast Cancer | Biotech Hunter | Biotech Hunter